COST UTILITY ANALYSIS OF ONCE-WEEKLY SEMAGLUTIDE AND DULAGLUTIDE FOR PATIENTS WITH TYPE 2 DIABETES IN SAUDI ARABIA

被引：0
|
作者：
Hassan, M. [1 ]
Barham, L. [2 ]
机构：
[1] Novo Nordisk, Riyadh 01, Saudi Arabia
[2] Univ South Wales, Learna Ltd Partnership, Royston, Hrt, England
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE23
引用
下载
收藏
页码：S54 / S54
页数：1
相关论文
共 50 条
  • [1] Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada
    Johansen, Pierre
    Hakan-Bloch, Jonas
    Liu, Aiden R.
    Bech, Peter G.
    Persson, Sofie
    Leiter, Lawrence A.
    PHARMACOECONOMICS-OPEN, 2019, 3 (04) : 537 - 550
  • [2] Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada
    Pierre Johansen
    Jonas Håkan-Bloch
    Aiden R. Liu
    Peter G. Bech
    Sofie Persson
    Lawrence A. Leiter
    PharmacoEconomics - Open, 2019, 3 : 537 - 550
  • [3] COST-UTILITY ANALYSIS OF ONCE-WEEKLY SEMAGLUTIDE VERSUS DULAGLUTIDE IN PATIENTS WITH TYPE 2 DIABETES REQUIRING TREATMENT WITH A GLP-1 RECEPTOR AGONIST
    Uranga, Garcia J.
    Jung, S.
    Dahaoui, Smeat
    VALUE IN HEALTH, 2022, 25 (12) : S160 - S160
  • [4] Cost-Utility Analysis of Once-Weekly Semaglutide, Dulaglutide, and Exenatide for Type 2 Diabetes Patients Receiving Metformin-Based Background Therapy in China
    Hu, Shanshan
    Wang, Shuowen
    Qi, Chendong
    Gu, Shengying
    Shi, Chenyang
    Mao, Lin
    Fan, Guorong
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [5] Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands
    Hunt, Barnaby
    Malkin, Samuel J. P.
    Moes, Robert G. J.
    Huisman, Eline L.
    Vandebrouck, Tom
    Wolffenbuttel, Bruce H. R.
    BMJ OPEN DIABETES RESEARCH & CARE, 2019, 7 (01)
  • [6] The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain
    Josep Vidal
    Samuel J. P. Malkin
    Barnaby Hunt
    Virginia Martín
    Nino Hallén
    Francisco Javier Ortega
    Diabetes Therapy, 2020, 11 : 509 - 521
  • [7] The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain
    Vidal, Josep
    Malkin, Samuel J. P.
    Hunt, Barnaby
    Martin, Virginia
    Hallen, Nino
    Javier Ortega, Francisco
    DIABETES THERAPY, 2020, 11 (02) : 509 - 521
  • [8] Lower Drug Cost of Successfully Treating Patients with Type 2 Diabetes to Targets with Once-Weekly Semaglutide versus Once-weekly Dulaglutide in Japan: A Short-Term Cost-Effectiveness Analysis
    Ataru Igarashi
    Barnaby Hunt
    Lars Wilkinson
    Jakob Langer
    Richard F. Pollock
    Advances in Therapy, 2020, 37 : 4446 - 4457
  • [9] Lower Drug Cost of Successfully Treating Patients with Type 2 Diabetes to Targets with Once-Weekly Semaglutide versus Once-weekly Dulaglutide in Japan: A Short-Term Cost-Effectiveness Analysis
    Igarashi, Ataru
    Hunt, Barnaby
    Wilkinson, Lars
    Langer, Jakob
    Pollock, Richard F.
    ADVANCES IN THERAPY, 2020, 37 (10) : 4446 - 4457
  • [10] COST-EFFECTIVENESS ANALYSIS OF ONCE-WEEKLY SEMAGLUTIDE FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES IN MEXICO
    Valdez-Huerta, R.
    Moreno, D.
    Hernandez, Paladio J. A.
    VALUE IN HEALTH, 2022, 25 (07) : S429 - S429
12345